NDA 216203 · Lexicon Pharms INC
Inpefa
Sotagliflozin · Oral · Sodium-Glucose Cotransporter 2 Inhibitor
NovelCDER novel approval, May 26, 2023: To treat heart failure
Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
May 26, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
54
22 Phase 3, 4 recruiting
FAERS reports
557
202 serious, 50 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 12, 2026.
INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors INPEFA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure ( 1 ) or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors ( 1 )
Mechanism: Sotagliflozin is an inhibitor of SGLT2 and SGLT1. Inhibiting SGLT2 reduces renal reabsorption of glucose and sodium which may influence several physiological functions such as lowering both pre-and afterload of the heart and downregulating sympathetic activity. Inhibiting SGLT1 reduces intestinal absorption of glucose and sodium which likely contributes to diarrhea. The mechanism for sotagliflozin's cardiovascular benefits has not been established.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 26, 2023 Original approval · Type 1 - New Molecular Entity NovelLabelMedication GuideLetter
2 products under this application
- INPEFA · SOTAGLIFLOZIN 400MG · TABLET, ORAL · Prescription
- INPEFA · SOTAGLIFLOZIN 200MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sotagliflozin" as an intervention, any sponsor and status, largest first.
- Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskPivotal-lookingTerminated
Lexicon PharmaceuticalsIndustry
NCT03315143 · 10,584 participants · Start Dec 19, 2017 · Primary completion Jul 8, 2020
Drug: Sotagliflozin; Placebo · For: Heart Failure; Type 2 Diabetes Mellitus; Chronic Kidney Diseases
Sites: Birmingham, Alabama; Sheffield, Alabama; Mesa, Arizona · 754 sites in all
- Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesPivotal-lookingRecruiting
Steno Diabetes Center CopenhagenAcademic, hospital or other
NCT06082063 · 2,000 participants (planned) · Start Jul 1, 2024 · Primary completion Jul 1, 2029
Drug: Aspirin tablet; Semaglutide and 2 more · For: Cardiovascular Diseases; Heart Failure; Type 1 Diabetes and 1 more
Sites: Copenhagen, Denmark; Herlev, Denmark
- A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy AlonePivotal-lookingCompleted
Lexicon PharmaceuticalsIndustry
NCT02531035 · 1,405 participants · Start Sep 2015 · Primary completion Apr 2017
Drug: Sotagliflozin; Placebo · For: Type 1 Diabetes Mellitus (T1DM); High Level of Sugar (Glucose) in the Blood
Sites: Concord, California; Escondido, California; La Jolla, California · 135 sites in all
- Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)Pivotal-lookingTerminated
Lexicon PharmaceuticalsIndustry
NCT03521934 · 1,222 participants · Start Jun 15, 2018 · Primary completion Jun 5, 2020
Drug: Sotagliflozin; Placebo · For: Heart Failure; Type 2 Diabetes Mellitus
Sites: Alexander City, Alabama; Cottonwood, Arizona; Little Rock, Arkansas · 466 sites in all
- Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin MonotherapyPivotal-lookingCompleted
Lexicon PharmaceuticalsIndustry
NCT03332771 · 954 participants · Start Dec 1, 2017 · Primary completion Aug 6, 2019
Drug: Sotagliflozin (SAR439954); Glimepiride and 3 more · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Little Rock, Arkansas; Anaheim, California · 142 sites in all
- Cardiovascular and Renal Protection With SGLT Inhibition in Kidney Transplant Recipients: The RENAISSANCE TrialPivotal-lookingNot yet recruiting
University of British ColumbiaAcademic, hospital or other
NCT07944326 · 900 participants (planned) · Start Apr 1, 2027 · Primary completion Oct 1, 2031
Drug: Sotagliflozin; Placebo · For: Kidney Transplant Recipient
Sites: Minneapolis, Minnesota; New York, New York; Chapel Hill, North Carolina · 25 sites in all
- Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin TherapyPivotal-lookingCompleted
Lexicon PharmaceuticalsIndustry
NCT02384941 · 793 participants · Start Mar 2015 · Primary completion Sep 2016
Drug: Placebo; Sotagliflozin · For: Type 1 Diabetes Mellitus
Sites: Birmingham, Alabama; Little Rock, Arkansas; Escondido, California · 75 sites in all
- Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar ControlPivotal-lookingCompleted
Lexicon PharmaceuticalsIndustry
NCT03242252 · 787 participants · Start Aug 16, 2017 · Primary completion Mar 25, 2019
Drug: Placebo; Sotagliflozin · For: Type 2 Diabetes Mellitus; Chronic Kidney Disease Stage 3
Sites: Birmingham, Alabama; Guntersville, Alabama; Phoenix, Arizona · 170 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness54
- diarrhoea50
- death47
- therapy interrupted37
- dyspnoea28
- off label use27
- product use issue27
- urinary tract infection25
- headache23
- nausea19
- fungal infection17
- drug ineffective15
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 6 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 45 |
| 2024 | 296 |
| 2025 | 146 |
| 2026 | 55 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Inpefa (Sotagliflozin)
2024 spending
$5.9M
Beneficiaries
2,006
7,368 claims
Per beneficiary
$2,922
$19.33 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $659,182 |
| 2024 | $5,862,205 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
Hamid AK, Tayem AA, Al-Aish ST, et al. · Ther Adv Cardiovasc Dis 2024 · Systematic Review, Meta-Analysis
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Bhatt DL, Szarek M, Pitt B, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Multicenter Study
- SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis.
Banerjee M, Pal R, Nair K, et al. · Indian Heart J 2023 · Meta-Analysis, Systematic Review
- Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.
Bhatt AS, Bhatt DL, Steg PG, et al. · J Am Coll Cardiol 2024 · Clinical Trial, Phase III, Multicenter Study
- Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
Kongmalai T, Hadnorntun P, Leelahavarong P, et al. · Front Endocrinol (Lausanne) 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Bhatt DL, Szarek M, Steg PG, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Lexicon Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.